NCT02484027 - Effect of Rosuvastatin on Prognosis of Clinical Response in Acute Ischemic Stroke Patients(REPAIRS) | Biotech Hunter

Enrollment

456

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2018

Conditions

Infarction, Anterior Cerebral Artery

Interventions

DRUG

Rosuvastatin

Patients will be randomly assigned to receive 2 different therapies for the first 3 days of hospitalization: no statins (non-statin-therapy group) or to immediately receive rosuvastatin orally at a dose of 20mg daily (statin-therapy group). From the fourth day onward, rosuvastatin 10 mg daily will be administered in all patients for 1 year

Trial Locations (1)

215004

Department of Neurology, Second Affiliated Hospital of Soochow University, Suzhou